Results 11 to 20 of about 2,458 (200)

Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial. [PDF]

Nat Med
PI3K-δ inhibitors have shown impressive activity in lymphoid malignancies but have been hampered by autoimmune and infectious toxicities, leading to market withdrawals. We previously demonstrated activity of the PI3K-δγ inhibitor duvelisib in T cell lymphomas (TCLs) that was associated with inflammatory adverse events.
Horwitz SM, Nirmal AJ, Rahman J, Xu R, Drill E, Galasso N, Ganesan N, Davey T, Hancock H, Perez L, Maccaro C, Bahgat A, Marzouk E, Cathcart E, Moskowitz A, Noy A, Kumar A, Jacobsen E, Fisher DC, Mehta-Shah N, Kim YH, Khodadoust M, Kotlov N, Nikitina A, Kudryashova O, Zubareva V, Zornikova K, Shin N, Sorokina M, Degryse S, Postovalova E, Bagaev A, Hosszu K, McAvoy D, Boelens JJ, Wu W, Ciantra Z, Appelt JW, Trevisani C, Amaka S, Weinstock DM, Vardhana SA.   +41 more
europepmc   +3 more sources

DUVELISIB, PI3K-DELTA/GAMMA INHIBITOR, PRETREATMENT ATTENUATES BORTEZOMIB-INDUCED NEUROPATHIC PAIN.

IBRO Neuroscience Reports, 2023
Jakub Slepička, Pavel Adamek, Jiří Paleček   +2 more
doaj   +2 more sources

Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomas

Blood Advances
: Patients with relapsed or refractory (R/R) peripheral T-cell lymphomas (PTCL) require lineage-specific therapies to bridge to hematopoietic stem cell transplantation (HSCT).
Josie G. Ford, Min Jung Koh, Alexandra W. Lenart, Caroline MacVicar, Kusha Chopra, Arushi Meharwal, Mark N. Sorial, Mwanasha Merrill, Anna B. Rider, Aliyah R. Sohani, Sean M. McCabe, Ronnie A. Nemec, Makoto Iwasaki, Dhruv Mistry, Khyati Maulik Kariya, Steven Chen, Jeffrey Barnes, Steven McAfee, Yi-Bin Chen, Corben Yuwai Wong, Kristiana Nasto, Eric Jacobsen, Salvia Jain   +22 more
doaj   +3 more sources

Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials

Frontiers in Immunology, 2023
BackgroundDuvelisib is the first FDA-approved oral dual inhibitor of phosphatidylinositol-3-kinase PI3K-delta (PI3K-δ) and PI3K-gamma (PI3K-γ). Although many clinical studies support the efficacy of duvelisib, the safety of duvelisib remains with great ...
Zhongwang Wang, Hui Zhou, Jing Xu, Jinjin Wang, Ting Niu   +4 more
doaj   +1 more source

Protein Kinase CK1α Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma

Frontiers in Oncology, 2021
Mantle Cell Lymphoma (MCL) is still an incurable B-cell malignancy characterized by poor prognosis and frequent relapses. B Cell Receptor (BCR) signaling inhibitors, in particular of the kinases BTK and PI3Kγ/δ, have demonstrated clinically meaningful ...
Sabrina Manni, Sabrina Manni, Anna Fregnani, Anna Fregnani, Laura Quotti Tubi, Laura Quotti Tubi, Zaira Spinello, Zaira Spinello, Marco Carraro, Marco Carraro, Greta Scapinello, Greta Scapinello, Andrea Visentin, Andrea Visentin, Gregorio Barilà, Gregorio Barilà, Marco Pizzi, Angelo Paolo Dei Tos, Fabrizio Vianello, Renato Zambello, Renato Zambello, Carmela Gurrieri, Carmela Gurrieri, Gianpietro Semenzato, Gianpietro Semenzato, Livio Trentin, Livio Trentin, Francesco Piazza, Francesco Piazza   +28 more
doaj   +1 more source

New pharmacotherapeutic approaches for the treatment of peripheral T-cell lymphoma

Фармакоэкономика, 2023
Today, it is difficult to overestimate the new directions in the pharmacotherapy of peripheral T-cell lymphomas (PTCL): immunotherapy, including adoptive, targeted therapy and chemotherapy.
M. А. Sorokina, A. V. Rakhteenko, T. R. Grishina   +2 more
doaj   +1 more source

Development and Validation of 96-Microwell-Based Spectrophotometric and High-Performance Liquid Chromatography with Fluorescence Detection Methods with High Throughput for Quantitation of Duvelisib and Seliciclib in Their Bulk Forms and Capsules

Applied Sciences, 2022
The Food and Drug Administration (FDA) has approved duvelisib (DUV) for managing follicular lymphoma, small lymphocytic lymphoma, and relapsed or refractory chronic lymphocytic leukemia.
Haya I. Aljohar, Abdulmajeed A. Alghamdi, Nasr Y. Khalil, Hany W. Darwish, Rashad Al-Salahi, Ibrahim A. Darwish   +5 more
doaj   +1 more source

In vivo activity of the dual PI3Kδ and PI3Kγ inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenografts [PDF]

, 2023
Background: Acute lymphoblastic leukemia (ALL) remains one of the most common causes of cancer-related mortality in children. Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases, and aberrations in the PI3K pathway are associated with ...
Earley, EJ, Erickson, SW, Evans, K, Hughes, K, Lock, RB , Pachter, JA, Randall, J, Smith, CM, Smith, MA, Teicher, BA, Watts, B   +10 more
core   +2 more sources

Development and Validation of a Novel Microwell-Based Fluorimetric Method Assisted with Fluorescence Plate Reader for High-Throughput Determination of Duvelisib: Application to the Analysis of Capsules and Plasma Samples

Applied Sciences, 2022
Duvelisib (DUV) is a novel drug with a small molecular weight and characterized by dual phosphoinositide-3-kinase (PI3K)- and PI3K-inhibitory activity. The Food and Drug Administration (FDA) recently approved DUV for the management of small lymphocytic ...
Abdullah M. Al-Hossaini, Hany W. Darwish, Ahmed Y. Sayed, Nasr Y. Khalil, Rashad Al-Salahi, Ibrahim A. Darwish   +5 more
doaj   +1 more source

Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma [PDF]

, 2021
Background: When treating indolent B-cell lymphoma, combining continuously administered oral phosphatidylinositol 3-kinase (PI3K) inhibitors with immunochemotherapy has been associated with toxicity.
Buvaylo V., Childs B. H., Dreyling M., Fletcher M., Leppa S., Matasar M. J., Pedersen M., Santoro A., Zinzani P. L.   +8 more
core   +4 more sources